{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/effective-planning-address-unmet-needs-prader-willi-syndrome-trials#webpage",
"url": "https://www.fortrea.com/insights/effective-planning-address-unmet-needs-prader-willi-syndrome-trials",
"name": "Effective planning to address unmet needs in Prader-Willi Syndrome trials",
"description": "Explore this Fortrea white paper on Prader-Willi Syndrome clinical trials and discover effective strategies for addressing unmet needs in Prader-Willi Syndrome drug development through patient-focused clinical research approaches. The white paper examines key challenges and opportunities in PWS clinical trials, including patient recruitment and retention, patient and caregiver engagement, endpoint selection, operational planning, protocol design considerations, advocacy group collaboration, and decentralized clinical trial approaches designed to reduce patient burden. Learn how patient-centric trial strategies, rare disease recruitment methods, clinical outcome assessments, family-centered engagement models, community partnerships, and operational best practices are helping sponsors improve study execution, enhance participant experiences, support enrollment and retention goals, and advance therapeutic development for individuals living with Prader-Willi Syndrome."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Effective planning to address unmet needs in Prader-Willi Syndrome trials",
"item": "https://www.fortrea.com/insights/effective-planning-address-unmet-needs-prader-willi-syndrome-trials"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/effective-planning-address-unmet-needs-prader-willi-syndrome-trials#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/effective-planning-address-unmet-needs-prader-willi-syndrome-trials#webpage"
},
"headline": "Prader-Willi Syndrome Clinical Trial Strategies & Development Considerations | Fortrea White Paper",
"description": "Explore this Fortrea white paper on Prader-Willi Syndrome clinical trials and discover effective strategies for addressing unmet needs in Prader-Willi Syndrome drug development through patient-focused clinical research approaches. The white paper examines key challenges and opportunities in PWS clinical trials, including patient recruitment and retention, patient and caregiver engagement, endpoint selection, operational planning, protocol design considerations, advocacy group collaboration, and decentralized clinical trial approaches designed to reduce patient burden. Learn how patient-centric trial strategies, rare disease recruitment methods, clinical outcome assessments, family-centered engagement models, community partnerships, and operational best practices are helping sponsors improve study execution, enhance participant experiences, support enrollment and retention goals, and advance therapeutic development for individuals living with Prader-Willi Syndrome.",
"genre": "White Paper",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2024-10-14",
"dateModified": "2024-10-14",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-02/prader-willi-syndrome-trials.pdf",
"encodingFormat": "application/pdf"
}
}
]
}